Panretinal Photocoagulation (PRP) Plus Ranibizumab for Proliferative Diabetic Retinopathy

Panretinal Photocoagulation Versus Panretinal Photocoagulation Plus Intravitreous Ranibizumab for High Risk Proliferative Diabetic Retinopathy

The purpose of this study is to evaluate the effects of panretinal photocoagulation plus intravitreal ranibizumab for the treatment of patients with high risk proliferative diabetic retinopathy in terms of changes in visual acuity and neovascularization area.

Inclusion Criteria:

• Age ≥ 18 years old
• High risk proliferative diabetic retinopathy
• Visual acuity ≥ 20/800
• No previous laser treatment for diabetic retinopathy

Exclusion Criteria:

• Previous pars plana vitrectomy
• Systemic thrombo-embolic events
• Uncontrolled systemic hypertension
• Conditions avoiding adequated documentation
• Previous eye surgery in the last 6 months before inclusion in the study